Johnson & Johnson on Tuesday beat analysts’ estimates for first-quarter profit on higher sales of its cancer drugs and consumer products including Tylenol, while cutting its full-year forecast due to coronavirus shutdowns.
J&J beats profit estimates but coronavirus fuels forecast cut